Literature DB >> 17079451

Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice.

Dana M Brantley-Sieders1, Wei Bin Fang, Yoonha Hwang, Donna Hicks, Jin Chen.   

Abstract

Ephrin-A1, the prototypic ligand for EphA receptor tyrosine kinases, is overexpressed in vascularized tumors relative to normal tissue. Moreover, ephrin-A1-Fc fusion proteins induce endothelial cell sprouting, migration, and assembly in vitro, and s.c. vascular remodeling in vivo. Based on these data, we hypothesized that native, membrane-bound ephrin-A1 regulates tumor angiogenesis and progression. We tested this hypothesis using a transplantable mouse mammary tumor model. Small interfering RNA-mediated ephrin-A1 knockdown in metastatic mammary tumor cells significantly diminishes lung metastasis without affecting tumor volume, invasion, intravasation, or lung colonization upon i.v. injection in vivo. Ephrin-A1 knockdown reduced tumor-induced endothelial cell migration in vitro and microvascular density in vivo. Conversely, overexpression of ephrin-A1 in nonmetastatic mammary tumor cells elevated microvascular density and vascular recruitment. Overexpression of ephrin-A1 elevated wild-type but not EphA2-deficient endothelial cell migration toward tumor cells, suggesting that activation of EphA2 on endothelial cells is one mechanism by which ephrin-A1 regulates angiogenesis. Furthermore, ephrin-A1 knockdown diminished, whereas overexpression of ephrin-A1 elevated, vascular endothelial growth factor (VEGF) levels in tumor cell-conditioned medium, suggesting that ephrin-A1-mediated modulation of the VEGF pathway is another mechanism by which membrane-tethered ephrin-A1 regulates angiogenic responses from initially distant host endothelium. These data suggest that ephrin-A1 is a proangiogenic signal, regulating VEGF expression and facilitating angiogenesis-dependent metastatic spread.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079451     DOI: 10.1158/0008-5472.CAN-06-1560

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  60 in total

Review 1.  Axon guidance molecules in vascular patterning.

Authors:  Ralf H Adams; Anne Eichmann
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03-31       Impact factor: 10.005

Review 2.  Eph receptors and ephrins in cancer: bidirectional signalling and beyond.

Authors:  Elena B Pasquale
Journal:  Nat Rev Cancer       Date:  2010-03       Impact factor: 60.716

3.  Small molecules can selectively inhibit ephrin binding to the EphA4 and EphA2 receptors.

Authors:  Roberta Noberini; Mitchell Koolpe; Satyamaheshwar Peddibhotla; Russell Dahl; Ying Su; Nicholas D P Cosford; Gregory P Roth; Elena B Pasquale
Journal:  J Biol Chem       Date:  2008-08-26       Impact factor: 5.157

4.  Hsp90 is an essential regulator of EphA2 receptor stability and signaling: implications for cancer cell migration and metastasis.

Authors:  Balasubramaniam Annamalai; Xueguang Liu; Udhayakumar Gopal; Jennifer S Isaacs
Journal:  Mol Cancer Res       Date:  2009-06-30       Impact factor: 5.852

5.  Transactivation of the receptor-tyrosine kinase ephrin receptor A2 is required for the low molecular weight hyaluronan-mediated angiogenesis that is implicated in tumor progression.

Authors:  Frances E Lennon; Tamara Mirzapoiazova; Nurbek Mambetsariev; Bolot Mambetsariev; Ravi Salgia; Patrick A Singleton
Journal:  J Biol Chem       Date:  2014-07-14       Impact factor: 5.157

6.  Intramyocardial administration of chimeric ephrinA1-Fc promotes tissue salvage following myocardial infarction in mice.

Authors:  Jessica L Dries; Susan D Kent; Jitka A I Virag
Journal:  J Physiol       Date:  2011-01-31       Impact factor: 5.182

Review 7.  The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting.

Authors:  Jill Wykosky; Waldemar Debinski
Journal:  Mol Cancer Res       Date:  2008-12       Impact factor: 5.852

8.  Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase.

Authors:  Wei Bin Fang; Dana M Brantley-Sieders; Yoonha Hwang; Amy-Joan L Ham; Jin Chen
Journal:  J Biol Chem       Date:  2008-04-03       Impact factor: 5.157

9.  Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls.

Authors:  J E Bohonowych; U Gopal; J S Isaacs
Journal:  J Oncol       Date:  2010-06-24       Impact factor: 4.375

10.  T cells redirected to EphA2 for the immunotherapy of glioblastoma.

Authors:  Kevin K H Chow; Swati Naik; Sunitha Kakarla; Vita S Brawley; Donald R Shaffer; Zhongzhen Yi; Nino Rainusso; Meng-Fen Wu; Hao Liu; Yvonne Kew; Robert G Grossman; Suzanne Powell; Dean Lee; Nabil Ahmed; Stephen Gottschalk
Journal:  Mol Ther       Date:  2012-10-16       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.